

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/04, A61K 31/70, A01N 63/00	A1	(11) International Publication Number: WO 97/28179 (43) International Publication Date: 7 August 1997 (07.08.97)
(21) International Application Number: PCT/US97/01434 (22) International Filing Date: 30 January 1997 (30.01.97) (30) Priority Data: 60/010,930 31 January 1996 (31.01.96) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US). (72) Inventors: FICK, James, R.; 1607 26th Avenue, San Francisco, CA 94122 (US). ISRAEL, Mark, A.; 3691 Dayhill Court, Martinez, GA 30907 (US). (74) Agent: BERLINER, Robert; Robbins, Berliner & Carson, 5th floor, 201 N. Figueroa Street, Los Angeles, CA 90012-2628 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: METHOD FOR INHIBITING TUMOR CELL GROWTH (57) Abstract The invention provides methods for the enhanced intracellular delivery of therapeutically active molecules to a target tumor cell. In a preferred embodiment, the method comprises providing engineered cells that express a heterologous nucleic acid that encodes a connexin and that contain a pro-drug activating gene that, when expressed, converts a nontoxic substrate to a therapeutic toxic metabolite, contacting target tumor cells in a solid tumor with engineered cells that form functional gap junctions with said target tumor cells, and exposing the engineered and tumor cells to the nontoxic substrate, whereby the nontoxic substrate is converted to a therapeutic molecule such that the therapeutic molecule passes through a gap junction to a target tumor cell.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

METHOD FOR INHIBITING TUMOR CELL GROWTH

This application is a continuation-in-part of U.S. provisional
5 application serial No. 60/010,930, filed on January 31, 1996.

BACKGROUND OF THE INVENTION

10

The invention relates to cancer therapies, to gene therapies for treating cancer, and to *in vivo* methods for transferring molecules from engineered cells into other cells.

15

A gap junction is a membrane structure detectable at points of contact between adjacent cells. Gap junctions mediate the intercellular passage of small molecules from the cytoplasm of one cell to that of the adjacent cell.

20

Gap junctions are composed of clusters of membrane proteins which form structures called connexons. The proteins are peripherally disposed around a central channel. Gap junction transmembrane passages are formed when a connexon of one cell aligns with a connexon of an adjacent cell. In this way, transmembrane intercellular pathways are

25

formed that permit the diffusion of molecules between coupled cells.

30

The diameter of the connexon channels, as measured by electron microscopy and X-ray crystallography, is about 1.5-2 nm. Based on this measurement, one would expect that only substances of less than approximately 1,000 daltons (ions, small molecules and synthetic oligonucleotides, but not macromolecules such as proteins and

polynucleotides) would enter the channel and pass from one cell to another. This prediction has been verified experimentally. Sugars, nucleic acids, amino acids, fatty acids, small peptides, and even drugs or carcinogens could pass between cells through gap junctions. Proteins, complex lipids, polysaccharides, RNA, and other large molecules do not. This intercellular channel flux of ions and molecules does not require energy and is due to passive diffusion.

The protein subunits of connexons may vary from cell to cell. Some connexons contain ductin. Finbow and Pitts, J. Cell Sci. 106: 463-472 (1993); Leitch and Finbow, Exp. Cell Res. 190: 218-226 (1990); Bohrmann, J. Cell Sci. 105: 513-518 (1993). Some connexons contain connexins. See Beyer *et al.*, J. Membr. Biol., 116:187-194 (1990), and references cited therein.

The best characterized of the connexon proteins, the connexins, are the gene products of a multi-gene family. More than a dozen connexins have been cloned.

Connexins are expressed in a cell-, tissue-, and developmentally specific manner. See Beyer *et al.*, J. Membr. Biol., 116:187-194 (1990); Dermietzel, R. *et al.*, Anat. Embryol., 182:517-258 (1990; Warner, A., Seminars in Cell Biology, 3:81-91 (1992); Kumar, N.M. *et al.*, Seminars in Cell Biology, 3:3-16 (1992). For instance, connexin43 is the predominant connexin expressed in cardiac muscle and in liver epithelial cells. In adult liver parenchymal cells, the predominant connexins are connexins32 and connexin26; nonparenchymal liver cells express other connexins. Each connexin forms channels with different conductance, regulatory, and permeability properties.

In those tissues where more than one connexin is expressed, gap junctions may contain more than one connexin. However, it is not known whether individual connexons may be comprised of more than one connexin type.

5

Individual cells that are coupled by gap junctions to neighboring cells do not always behave as discrete entities. Rather, two or more coupled cells often function in a highly integrated manner. Instead of responding individually to certain environmental stimuli, they respond as
10 a unit. In this way tissues can buffer or eliminate toxic compounds that would otherwise be harmful to individual cells, healthy cells can nourish injured cells, and critical molecules can be distributed among cells to coordinate local functions. For example, it has been proposed that gap functions play an important role in the function of cardiac muscle cells.
15 The rapid intercellular exchange of ions through gap junctions is believed to mediate coordinated contraction of the myocardium.

Gap junctional communication appears to contribute to what has been variously termed the "kiss of death," the "kiss of life" or the
20 "bystander effect". When cells that are normally insensitive to a given substance are connected via gap junctions to cells that are normally sensitive, the insensitive cells become sensitive ("kiss of death"), reportedly because of the passage of toxic molecules from the sensitive to the insensitive cells. On the other hand, when certain cells that are
25 unable to survive in defined tissue culture media are joined to cells that are capable of surviving, in some instances the sensitive cells acquire the ability to survive, reportedly because of the passage of molecules from survivalist cells to sensitive cells ("kiss of life").

30 The ability of adjacent cells to form gap junctions that link them is dependent on a number of factors:

- 5 a) the ability of cells to interact with neighboring cells. It has been reported that the presence of compatible cell adhesion molecules is an important requirement of gap junctional formation between adjacent cells. See Edelman, G.M., Biochem. 27:3533-3543 (1988); Meyer, R.A. *et al.*, J. Cell Biol. 119:179-189 (1992); Keane, R.W. *et al.*, J. Cell Biol. 106:1307-1319 (1988); Musil, L.S. *et al.*, J. Cell Biol. 111:2077-2087 (1990); Jongen *et al.*, J. Cell Biol. 114:545-555 (1991); Hofer *et al.* J. Neuroscience 16(14):4311-21 (1996).
- 10 b) it has been reported that increased levels of connexon protein expression results in increased gap junction communication. See Eghabali *et al.*, Proc. Natl. Acad. Sci. USA, 87:1328-1331 (1990); Zhu *et al.*, Proc. Natl. Acad. Sci. USA, 89:10218-10221 (1992); and Zhu *et al.*, Proc. Natl. Acad. Sci. USA, 88:1883-1887 (1991); Mesnil *et al.* Proc. Natl. Acad. Sci. USA, 93(5):1831-5.(1996); Bruzzone *et al.* Eur. J. Biochem. 238(1):1-27 (1996); Shinoura *et al.*, J. Neurosurg. 84(5):839-45 (1996) Fishman *et al.*, Cell Adhesion and Communication 3(4):353-65 (1995); Elfgang *et al.* J. Cell Biol. 129(3):805-17 (1995); Koval *et al.*, J. Cell Biol. 130(4):987-95 (1995); Moore *et al.*, Amer. J. Physiol. 267(5 Pt 1):C1371-80 (1994);
- 15 c) whether the connexon proteins expressed by one cell are capable of forming a connexon that is capable of linking with a connexon of a second cell to form a functional channel.
- 20 d) whether a molecule such as a carcinogen or the product of an oncogene is expressed in a cell, that interferes with the
- 25
- 30

normal function of any cellular protein that mediates cell to cell gap junctional communication. See Holder *et al.*, Cancer Research, 53:3475-3485 (1993).

5 It has been reported that cancer cells exhibit reductions in gap junction-mediated intercellular communication compared to normal cells with a similar tissue origin. While neoplastic cells can sometimes form gap junctions with other types of cells (heterologous coupling), it is recognized that gap function formation between cells of a similar type
10 (homologous coupling) is more efficient.

 It has been repeatedly observed that coupling normal cells to tumor cells slows down the growth of tumor cells. Also, experimental techniques that result in an increase in gap function channels can reduce
15 cellular proliferation and tumorigenicity.

 Since gap junctional communication appears to play a role in neoplasia, it has been suggested that increasing gap junctional communication should reverse neoplasia. Connexin gene expression can
20 be increased in malignant cell lines by the introduction of connexin genes. The proliferation rate of tumor cell growth in tissue culture, as well as tumor formation after injection into animals have been found to be reduced in cells that were genetically engineered to overexpress connexin genes.

25

 A new method for tumor gene therapy uses recombinant retroviral vectors containing a gene that encodes the thymidine kinase enzyme of the herpes simplex virus (HSVtk). Following infection of a tumor cell by the retroviral vector, the HSVtk gene is expressed therein. The HSVtk
30 enzyme avidly phosphorylates certain nucleoside analogues, such as the drug ganciclovir, for which normal mammalian thymidine kinase has a

6

poor affinity. These phosphorylated analogues are incorporated into the cellular genome during DNA replication, leading to tumor cell death. Exposure to ganciclovir does not appear to harm normal cells when given in therapeutic doses.

5

A recognized limitation of this therapy is the relative inefficiency of gene transfer. Also, retroviral particles are relatively rapidly inactivated by host organism defenses, such as complement. In addition, a target cell must be replicating for the DNA to be stably integrated. Only a minority
10 of tumor cells can be genetically altered after retroviral infection, especially *in vivo*.

SUMMARY OF THE INVENTION

It is a principal object of the invention to provide methods for treating tumors, especially rapidly growing tumors, in subjects in need thereof. In particular, it is an object of the invention to provide cells that are genetically engineered to increase their ability to interact with and to inhibit tumor cells. Still more particularly, it is an objective to provide cells that are genetically engineered to synthesize or modify molecules that can pass through gap junctions and inhibit the growth of tumor cells.

Accordingly, the present invention provides methods of inhibiting the growth of tumor cells, which methods comprise:

- a) providing engineered non-tumorigenic cells that express a first heterologous nucleic acid that encodes a molecule which enables, mediates or enhances the gap junctional transport of therapeutic molecules and a second heterologous nucleic acid which encodes a molecule with desired biological effects capable of passing through a gap junction or a pro-drug activating molecule that converts a non-toxic substrate to a toxic metabolite.
- b) contacting tumor cells in a solid tumor with cells of step a that form functional gap junctions with said tumor cells, and then
- c) in the case of therapeutic strategies utilizing pro-drug activating molecules, exposing the engineered and tumor cells to the non-toxic substrate, whereby the non-toxic substrate is converted to the toxic metabolite in cells that expresses the pro-drug activating molecule, and the toxic

metabolite then passes through gap junctions to adjacent coupled tumor cells, thereby inhibiting the cell growth of the tumor cells that contain the toxic metabolite.

5 The engineered cells may be derived from neoplastic and nonneoplastic established cell lines, cells from primary cultures established from tumor specimens, cultured cells from serial passages of surgical tumor specimens, and cultured cells isolated from normal tissues. Cell types include, but are not limited to, fibroblast, endothelial, smooth
10 and skeletal muscle, parenchymal, hematopoietic, lymphoid, epithelial, neuroectodermal, mesodermal, mesenchymal, bone or keratinocyte cell lines. These cells include, but are not limited to, rodent, feline, canine, bovine, equine, ovine, nonhuman primate, or human origin. A particular example are murine PA317 fibroblasts. The tumors to be treated include
15 all types of neoplastic cells. The pro-drug system involves, for example, thymidine kinase, cytosine deaminase, or β -glucosidase. Molecules that enable, mediate or enhance gap junctional transport include, but are not limited to, cadherins; connexins; catenins; ductin; desmocollin; desmoglein; desmoplakin; plakoglobin; cytoskeleton proteins such as
20 ankyrin, ezrin, fodrin, moesin, paxilin, radixin, talin, tensin, and vinculin; APC protein; DCC protein; Wnt proteins; integrins; and tight junction proteins such as ZO-1 and occludin.

The present invention further comprises methods for the enhanced
25 intracellular delivery of one or more therapeutically active molecules to target tumor cells, which method comprises:

- a) providing engineered cells that contain or can generate a therapeutically active molecule that passes through gap
30 junctional channels, wherein the engineered cells express a heterologous nucleic acid that encodes a molecule that

enables or enhances the extent of gap junction mediated intercellular communication. Such molecules include but are not limited to cellular adhesion molecules or connexon proteins that are expressed by the tumor cells described in step b, and

5

- b) contacting target tumor cells in a solid tumor with cells of step a that form functional gap junctions with said target tumor cells, whereby the molecule passes through a gap junction to a target tumor cell.

10

The invention further comprises compositions for the enhanced delivery of toxic metabolites to target tumor cells, which compositions comprise engineered cells that express a first heterologous nucleic acid that encodes a connexon protein and a second heterologous nucleic acid that encodes a therapeutic small molecule or a pro-drug activating molecule, and optionally a molecule other than a connexon protein that enables, mediates or enhances gap junctional intercellular communication.

15

20

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 depicts the coupling achieved between cells in tissue culture.

5

Fig. 2 depicts the bystander killing effect achieved between cells in tissue culture.

Fig. 3 illustrates that *in vivo* Ganciclovir (GCV) tumor toxicity increases as a function of ability to carry out gap junction-mediated intercellular communication.

Fig. 4 illustrates that injecting HSVtk-expressing fibroblasts into *pre-existing* tumors is effective to decrease tumor mass, and that the toxicity is greater in tumors with higher gap junction mediated intercellular transport.

Fig. 5 illustrates that the expression of connexon proteins such as connexin43 modulates GCV tumor toxicity.

20

Fig. 6 summarizes the effects of regulating connexon protein expression on GCV tumor toxicity *in vivo*.

DETAILED DESCRIPTION OF THE INVENTION

The patents and publications cited in this disclosure reflect the level
5 of skill in the art to which this invention pertains and are herein individually
incorporated by reference for all puposes.

Unless defined otherwise, all technical and scientific terms used
herein have the same meaning as commonly understood by one of
10 ordinary skill in the art to which this invention belongs. Singleton *et al.*,
Dictionary of Microbiology and Molecular Biology, second edition, John
Wiley and Sons (New York) (1994), provides one of skill with a general
dictionary of many of the terms used in this invention. Although any
methods and materials similar or equivalent to those described herein can
15 be used in the practice or testing of the present invention, the preferred
methods and materials are described. For purposes of the present
invention, the following terms are defined below.

A. Definitions

20

The term "tumor cell" or "cancer cell" or "neoplastic cell" denotes
a cell that demonstrates inappropriate, unregulated proliferation. A
"human" tumor is comprised of cells that have human chromosomes.
Such tumors include those in a human patient, and tumors resulting from
25 the introduction into a nonhuman host animal of a malignant cell line
having human chromosomes into a nonhuman host animal.

"Non-tumorigenic cell" is a cell that is unable to form a tumor when
introduced into a host organism. Examples include fibroblasts, epithelial
30 cells, endothelial cells, bone cells, keratinocytes, and any cell that can be
cultured in tissue culture, including tissue explants. Another kind of non-

tumorigenic cells are cells that are normally tumorigenic but are treated to remove their tumorigenicity, for example, irradiated, engineered non-tumorigenic cells derived from tumors.

5 The phrase "inhibiting cell growth" or "inhibiting tumor growth" generally means that the rate of increase in mass, size, number and/or the metabolism of treated cells and/or tumors is slower as a result of treatment than that of nontreated cells and/or tumors. The growth of a cell line or tumor is said to be "inhibited" by a treatment if, when assayed
10 by means such as radioisotope incorporation into the cells, the treated cells increase in number at a rate that is less than the proliferation rate of untreated control cells, and preferably less than about 50% of the untreated cell proliferation rate. More preferably, the growth rate is inhibited by at least 80%. If growth is assayed by a means such as
15 plating in methylcellulose, the growth of a cell line is said to be "inhibited" if the treated cells give rise to less than the number of colonies that grow from a like number of untreated cells. Preferably, the number of colonies from treated cells is less than about 70% of the number from untreated cells. More preferably, the number of colonies is decreased by at least
20 50%. "Inhibition of cell growth" also encompasses zero growth and, most importantly, consequent death of the tumor cells and eradication of the tumor. When measured *in vivo*, "inhibition of tumor growth" encompasses fewer or smaller tumors (for example, smaller diameter) as compared to control animals or untreated patients.

25

Inhibition can be evaluated by any accepted method of measuring whether growth or size of the tumor and/or increase in the number of cancerous or tumor cells has been slowed, stopped, or reversed. This includes direct observation and indirect evaluation such as subjective
30 symptoms or objective signs. The clinician may notice a decrease in tumor size or tumor burden (number of tumors) based on physical exam,

laboratory parameters, tumor markers, or radiographic findings. Alternatively, if the mammal is human, the patient may note improved vigor or vitality or decreased pain as subjective symptoms of improvement or response to therapy. Some laboratory signs that the clinician may
5 observe for response to therapy include normalization of tests such as white blood cell count, red blood cell count, platelet count, erythrocyte sedimentation rate, and various enzyme levels such as transaminases and hydrogenases. Additionally, the clinician may observe a decrease in a detectable tumor marker such as prostatic specific antigen (PSA) or chorio
10 embryonic antigen (CEA). Alternatively, other tests can be used to evaluate objective improvement such as sonograms, computerized axial tomography scans, nuclear magnetic resonance scans and positron emission testing.

15 The term "nucleic acid" refers to deoxyribonucleotides or ribonucleotides, and polymers thereof in either single- or double-stranded form, and unless specifically limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise
20 indicated, a particular nucleic acid sequence implicitly encompasses conservatively modified variants thereof and complementary sequences and as well as the sequence explicitly indicated. The term nucleic acid is used interchangeably with gene and cDNA.

25 The phrase "heterologous nucleic acid" generally denotes a nucleic acid that has been isolated, cloned and introduced into and/or expressed in a cell or cellular environment other than the cell or cellular environment in which said nucleic acid or protein may typically be found in nature. The term encompasses both nucleic acids originally obtained from a different
30 organism or cell type than the cell type in which it is expressed, and also

nucleic acids that are obtained from the same cell line as the cell line in which it is expressed.

The phrase "a nucleic acid sequence encoding" refers to a nucleic acid which contains sequence information that, if translated, yields the primary amino acid sequence of a specific protein or peptide. This phrase specifically encompasses degenerate codons (*i.e.*, different codons which encode a single amino acid) of the native sequence or sequences which may be introduced to conform with codon preference in a specific host cell.

The term "recombinant" or "engineered" when used with reference to a cell indicates that the cell replicates or expresses a nucleic acid or expresses a peptide or protein encoded by a nucleic acid, whose origin is exogenous to the cell. Recombinant cells can express nucleic acids that are not found within the native (nonrecombinant) form of the cell. Recombinant cells can also express nucleic acids found in the native form of the cell wherein the nucleic acids are re-introduced into the cell by artificial means.

20

The phrase "cellular adhesion molecules" denotes molecules or complexes of molecules present at the external surfaces of cells that mediate the contact and/or recognition and/or adhesion of adjoining cells. Pouliot *et al.*, BioEssays 14:743-748 (1992). Molecules which enable, mediate or enhance gap junction mediated intercellular communication include, but are not limited to, cadherins (Walsh, F.S. *et al.*, J. Neurochem., 55:805-812 (1990); Bussemakers, M.J. *et al.*, Mol. Biol. Rep., 17:123-128 (1993); Grumet, M. *et al.*, J. Cell Biol., 113:1399-1412 (1991); Shimoyama, Y. *et al.*, J. Cell Biol., 109:1787-1794 (1989); Suzuki, S. *et al.*, Cell Regul., 2:261-270 (1991); Tanihara, H. *et al.*, Cell Adhesion Commun., 2:15-26 (1994); Tanihara, H. *et al.*, Cell Adhesion Commun.,

30

- 2:15-26 (1994); Okazaki *et al.* J. Biol. Chem. 269 (16): 12092-8 (1994)
Breviario, F. *et al.*, Arterioscler. Thromb. Vasc. Biol., 15:1229-1239 (1995);
and Selig, S. *et al.*, Proc. Natl. Acad. Sci. USA, 92:3702-3706 (1995));
connexins (Fishman, G.I. *et al.*, Genomics, 10:250-256 (1991); Lee, S.W.
5 *et al.*, J. Cell Biol., 118:1213-1221 (1992); Reed, K.E. *et al.*, J. Clin.
Invest.; Dahl *et al.*, J. Biol. Chem. 271: 17903-10 (1996); 91:997-1004
(1993); Willecke, K. *et al.*, Eur. J. Cell Biol., 58:81-89 (1992); Paul, D.L.
et al., J. Cell Biol., 115:1077-1089 (1991); Haefliger, J.A. *et al.*, J. Biol.
Chem., 267:2057-2064 (1992); ; Willecke, K. *et al.*, Eur. J. Cell Biol., 56:1-
10 7 (1991); Haefliger, J.A. *et al.*, J. Biol. Chem. 267: 2057-64 (1992); and
Tucker, M.A. *et al.*, Exp. Cell Res., 213:224-230 (1994)); catenins
(Hulsken, J. *et al.*, J. Cell Biol., 127:2061-2069 (1994); Rimm, D. *et al.*,
Biochem. Biophys. Res. Commun., 203:1691-1699 (1994); Rimm, D.L. *et al.*,
"Molecular Cloning Reveals Alternative Splice Forms of Human
15 alpha(E)-catenin," unpublished (1993); Lo *et al.* J. Biol. Chem. 269 (35):
22310-9 (1994); and Furukawa, Y. *et al.*, Cytogenet. Cell Genet., 65:74-78
(1994)); ductin (Finbow, M.E. *et al.*, J. Cell Sci., 107:1817-1824 (1994));
desmocollin (Parker, A.E. *et al.*, J. Biol. Chem., 266:10438-10445 (1991));
desmoglein (Buxton, R.S. (1990); Schaefer, S. *et al.*, "Cytoskeletal
20 Architecture and Epithelial Differentiation: Molecular Determinations of Cell
Interactions Cytoskeletal Filament Anchorage," unpublished; Zimbelmann,
R. (1993); and Schafer, S. *et al.*, Exp. Cell Res., 211:391-399 (1994));
desmoplakin (Virata, M.L. *et al.*, Proc. Natl. Acad. Sci. USA, 89:544-548
(1992)); plakoglobin (Franke, W.W. *et al.*, Proc. Natl. Acad. Sci. USA,
25 86:4027-4031 (1989)); cytoskeleton proteins such as ankyrin (Lux, S.E.
et al., Nature, 344:36-42 (1990); Otto, E. *et al.*, J. Cell Biol., 114:241-253
(1991); and Lamert, S. *et al.*, Proc. Natl. Acad. Sci. USA, 87:1730-1734
(1990)), ezrin (Hunter, T. (1990); and Gould, K.L. *et al.*, Embo. J., 8:4133-
4142 (1989)), fodrin, moesin (Lankes, W.T. *et al.*, Proc. Natl. Acad. Sci.
30 USA (in press) (1991)), paxilin, radixin (Wilgenbus, K.K. *et al.*, Genomics,
16:199-206 (1993)), talin (Rees, D.J. *et al.*, Nature, 347:685-689 (1990);

and Liew, C.C. *et al.*, Proc. Natl. Acad. Sci. USA, 91:10645-10649 (1994)),
tensin (Chen, L.B., "Full Length Nucleotide Sequence of Tensin from a
Chicken Embryo Fibroblast cDNA Library," unpublished (1992); Davis *et*
al., Science 252 (5006): 712-5 (1991); and Liew, C.C. *et al.*, Proc. Natl.
5 Acad. Sci. USA, 91:10645-10649 (1994)), and vinculin (Weller, P.A. *et al.*,
Proc. Natl. Acad. Sci. USA, 87:5667-5671 (1990)); APC protein (Kinzler,
K.W. *et al.*, Science, 253:661-665 (1991)); DCC protein (Cooper, H.M. *et*
al., unpublished (1995); Hedrick, L. *et al.*, Genes Dev., 8:1174-1183
(1994); and Cho, K.R. *et al.*, Genomics, 19:525-531 (1994)); Wnt proteins
10 (Gavin, B.J. *et al.*, Genes Dev., 4:2319-2332 (1990)); integrins (Takada,
Y. *et al.*, J. Cell Biol., 109:397-407 (1989); and Takada, Y. *et al.*, Embo.
J., 8:1361-1368 (1989)); and tight junction proteins such as ZO-1 and
occludin (Willott, E. *et al.*, Am. J. Physiol., 262:1119-1124 (1992); Willott,
E. *et al.*, Proc. Natl. Acad. Sci. USA, 90:7834-8 (1993); and Furuse, M. *et*
15 *al.*, J. Cell Biol., 123:1777-1788 (1993)). The connexin is, for example,
connexin 26, 32, 43, or 45. The sequences of these proteins have been
published, and many are available from the American Type Tissue
Collection or from commercial sources. The engineered cells and the
target cells may be obtained or derived from the same individual, different
20 individuals, or different species.

The term "connexon protein" denotes a protein that forms part of the physical structure of a connexon. Examples include connexins and ductins.

5 The term "connexin" denotes a family of genes and gene products wherein the gene products are structural subunits of gap junctions, and conservatively modified variants thereof. "Connexin" further denotes nucleic acid sequences and their gene products, wherein the gene products are recognized by antibodies that specifically bind to a connexin
10 protein and, when expressed in cells, may be present in gap junctions. For a discussion of the connexin family of proteins, see Beyer *et al.*, J. Membr. Biol., 116:187-194 (1990), and references cited therein.

"Ductin" refers to gap junctional components described in Finbow
15 and Pitts (1993), J. Cell Sci. 106: 463-472; Leitch and Finbow (1990), Exp. Cell Res. 190: 218-226; Bohrmann (1993), J. Cell Sci. 105: 513-518. Ductin further denotes nucleic acid sequences and their gene products which, when expressed in cells, may be present in gap junctions, and wherein the gene products are recognized by antibodies that specifically
20 bind to a ductin protein.

"Coupled cells" or "gap junctional partners" denotes adjacent cells whose cytoplasmic domains are connected by gap junctions. That is, molecules may pass from one cell to the other via the gap junctions.

25

The term "pro-drug" refers to substances that are themselves not substantially toxic at therapeutic doses, but that become very toxic, either when chemically altered or metabolized by cells capable of altering or metabolizing the pro-drug, or when combined with other substances to
30 form a complex that is toxic. Examples include 5-fluorocytosine ("5FC"), which can be converted to the lethal metabolite 5-fluorouracil ("5FU"); 5-

methoxypurine arabinoside; and ganciclovir. A "therapeutic dose" or therapeutic amount of a pro-drug is a dose that causes substantially no ill effects to an organism except to cells that are capable of converting the pro-drug to a toxic product (*i.e.*, metabolite or complex). "Pro-drug
5 activating molecule" refers to a molecule such as an enzyme that is capable of metabolizing the non-toxic pro-drug to its toxic metabolite, or a molecule that combines (covalently or non-covalently) with a pro-drug to yield a toxic product.

10 The phrase "expresses a pro-drug sensitivity" signifies that a cell is rendered susceptible to a pro-drug by virtue of expressing a gene product that is capable of converting a nontoxic pro-drug into a cytotoxic chemical substance or complex. For example, the enzyme cytosine deaminase converts 5-fluorocytosine ("5FC") into the lethal metabolite 5-
15 fluorouracil ("5FU"). Host cells that are induced to produce cytosine deaminase by virtue of having the cytosine deaminase gene introduced into and expressed in the host cell, when exposed to 5FC, will die as a result of the formation of 5FU. Another gene that confers drug sensitivity upon a host cell is the thymidine kinase gene, which confers sensitivity to
20 ganciclovir. See Ido *et al.*, Cancer Research, 55:3105 (1995); Izquierdo *et al.*, Gene Therapy, 2:66 (1995). Other such "drug sensitivity" or
"suicide" genes are known in the art, and are expressly encompassed by the present invention.

25 It should be noted that treatments such as ganciclovir treatment are effective in cells that are undergoing cell division. Thus, terminally differentiated non-dividing cells such as most neurons do not exhibit marked growth inhibition upon treatment. Dividing tumor cells that are exposed to the pro-drug and/or its toxic metabolite, on the other hand,
30 should have their growth inhibited.

The phrase "heterologous nucleic acid that encodes a molecule that enables, mediates or enhances gap junctional communication" in the context of the claims includes, but is not limited to, nucleic acids encoding cadherins; catenins; desmocollin; desmoglein; desmoplakin; plakoglobin; cytoskeleton proteins such as ankyrin, ezrin, fodrin, moesin, paxilin, radixin, talin, tensin, and vinculin; APC protein; DCC protein; Wnt proteins; integrins; and tight junction proteins such as ZO-1 and occludin.

The phrase "a therapeutically active molecule" means a molecule that can pass from one junctional partner to another through gap junctional channels and that alters the chemistry, growth, or metabolism of the cell into which it passes.

The phrase "effective amount" means a dosage sufficient to produce a desired result. The desired result can be subjective or objective improvement in the recipient of the dosage, a decrease in tumor size, a decrease in the rate of growth of cancer cells, a decrease in metastasis, or any combination of the above.

B. General methods for introduction of connexon protein or selected genes into cells

An important aspect of this invention are methods for introducing connexon proteins and/or selected genes (e.g., pro-drug sensitivity genes) into cells. Standard eukaryotic transduction methods are used to produce cell lines which express connexon protein and, optionally, a drug resistance gene. It is expected that those of skill in the art are knowledgeable in the numerous systems available for transferring, cloning and expressing nucleic acids.

In brief summary, the expression of natural or synthetic nucleic acids is typically achieved by operably linking a nucleic acid of interest (e.g., one encoding connexin) to a promoter (which is either constitutive or inducible) and incorporating the construct into an expression vector.

5 The vectors are suitable for replication and integration in prokaryotes, eukaryotes, or preferably both. Typical cloning vectors contain transcription and translation terminators, transcription and translation initiation sequences, and promoters useful for regulation of the expression of the particular nucleic acid. The vectors optionally comprise expression

10 cassettes containing at least one independent terminator sequence, sequences permitting replication of the cassette in eukaryotes, or prokaryotes, or both, (e.g., shuttle vectors) and selection markers for both prokaryotic and eukaryotic systems. See Gilman and Smith, Gene, 8:81-97 (1979); Roberts *et al.*, Nature, 328:731-734 (1987); Berger and

15 Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology, volume 152, Academic Press, Inc., San Diego, CA (Berger); Sambrook *et al.*, Molecular Cloning - A Laboratory Manual (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, N.Y. (1989), (Sambrook); and Ausubel, F.M. *et al.*, Current Protocols in Molecular

20 Biology, eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1994 Supplement) (Ausubel). Product information from manufacturers of biological reagents and experimental equipment also provide information useful in known biological methods. Such manufacturers include the

25 SIGMA chemical company (Saint Louis, MO), R&D systems (Minneapolis, MN), Pharmacia LKB Biotechnology (Piscataway, NJ), CLONTECH Laboratories, Inc. (Palo Alto, CA), Chem Genes Corp., Aldrich Chemical Company (Milwaukee, WI), Glen Research, Inc., GIBCO BRL Life Technologies, Inc. (Gaithersburg, MD), Fluka Chemica-Biochemika

30 Analytika (Fluka Chemie AG, Buchs, Switzerland), and Applied

Biosystems (Foster City, CA), as well as many other commercial sources known to one of skill.

The expression vector typically comprises a prokaryotic replicon
5 covalently linked to an eukaryotic transcription unit or expression cassette that contains all the elements required for the expression of exogenous connexon protein in eukaryotic cells. A typical expression cassette contains a promoter linked to the DNA sequence encoding the selected connexon protein and signals required for efficient polyadenylation of the
10 transcript.

Eukaryotic promoters typically contain at least two types of regulatory sequences, the TATA box and upstream promoter elements. The TATA box, located 25-30 base pairs upstream of the transcription
15 initiation site, is thought to be involved in directing RNA polymerase to begin RNA synthesis. The other upstream promoter elements may determine the rate at which transcription is initiated.

Enhancer elements can stimulate transcription up to 1,000 fold from
20 linked homologous or heterologous promoters. Enhancers are active when placed downstream or upstream from the transcription initiation site. Many enhancer elements derived from viruses have a broad host range and are active in a variety of tissues. For example, the SV40 early gene enhancer is suitable for many cell types. Other enhancer/promoter
25 combinations that are suitable for the present invention include those derived from polyoma virus, human or murine cytomegalovirus, the long term repeat from various retroviruses such as murine leukemia virus, murine or Rous sarcoma virus and HIV. See Enhancers and Eukaryotic Expression, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1983),
30 which is incorporated herein by reference.

In the construction of the expression cassette, the promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance
5 can be accommodated without loss of promoter function.

In addition to a promoter sequence, the expression cassette should also contain a transcription termination region downstream of the connexon protein structural gene to provide for efficient termination. The
10 termination region may be obtained from the same source as the promoter sequence or may be obtained from a different source.

If the mRNA encoded by the connexon protein structural gene is to be efficiently translated, polyadenylation sequences are also commonly
15 added to the vector construct. Two distinct sequence elements are required for accurate and efficient polyadenylation: GU or U rich sequences located downstream from the polyadenylation site and a highly conserved sequence of six nucleotides, AAUAAA, located 11-30 nucleotides upstream. Termination and polyadenylation signals that are
20 suitable for the present invention include those derived from SV40, or a partial genomic copy of a gene already resident on the expression vector.

In addition to the elements already described, the expression vector of the present invention may typically contain other specialized elements
25 intended to increase the level of expression of cloned nucleic acids or to facilitate the identification of cells that carry the transduced DNA. For instance, a number of animal viruses contain DNA sequences that promote the extra chromosomal replication of the viral genome in permissive cell types. Plasmids bearing these viral replicons are
30 replicated episomally as long as the appropriate factors are provided by genes either carried on the plasmid or with the genome of the host cell.

The vector may or may not comprise a eukaryotic replicon. If a eukaryotic replicon is present, then the vector may be amplifiable in eukaryotic cells using the appropriate selectable marker. If the vector does not comprise a eukaryotic replicon, no episomal amplification is possible. Instead, the transduced DNA integrates into the genome of the engineered cell, where the promoter directs expression of the desired nucleic acid.

The vectors may include selectable markers which can be used for nucleic acid amplification such as the sodium, potassium ATPase, thymidine kinase, aminoglycoside phosphotransferase, hygromycin B phosphotransferase, xanthine-guanine phosphoribosyl transferase, CAD (carbamyl phosphate synthetase, aspartate transcarbamylase, and dihydroorotase), adenosine deaminase, dihydrofolate reductase, and asparagine synthetase and ouabain selection. Alternatively, high yield expression systems not involving nucleic acid amplification are also suitable, such as using a baculovirus vector in insect cells, with connexon protein encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.

20

The expression vectors of the present invention will typically contain both prokaryotic sequences that facilitate the cloning of the vector in bacteria as well as one or more eukaryotic transcription units that are expressed only in eukaryotic cells, such as mammalian cells. The prokaryotic sequences are preferably chosen such that they do not interfere with the replication of the DNA in eukaryotic cells.

25

Once a nucleic acid is synthesized or isolated and inserted into a vector and cloned, one may express the nucleic acid in a variety of recombinantly engineered cells known to those of skill in the art. Expression of a an exogenous nucleic acid can be enhanced by including

30

multiple copies of, for example, a connexon protein-encoding nucleic acid in an engineered cell, by selecting a vector known to reproduce in the host, thereby producing large quantities of protein from exogenous inserted DNA (such as pUC8, ptac12, or pIN-III-ompA1, 2, or 3), or by any other known means of enhancing peptide expression. Connexon protein molecules will be expressed when the DNA sequence is functionally inserted into a vector. "Functionally inserted" means that it is inserted in proper reading frame and orientation and operably linked to proper regulatory elements. Typically, a connexon protein gene will be inserted downstream from a promoter and will be followed by a stop codon, although production as a hybrid protein followed by cleavage may be used, if desired.

1. **Vectors for introduction and expression of connexon protein in cells**

Vectors to which connexon protein-encoding nucleic acids are operably linked may be used to introduce these nucleic acids into host cells and mediate their replication and/or expression. "Cloning vectors" are useful for replicating and amplifying the foreign nucleic acids and obtaining clones of specific foreign nucleic acid-containing vectors. "Expression vectors" mediate the expression of the foreign nucleic acid. Some vectors are both cloning and expression vectors.

In general, the particular eukaryotic expression vector used to transport connexon protein or any other gene into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic cells may be used. Expression vectors containing regulatory elements from eukaryotic viruses such as retroviruses are typically used. SV40 vectors include pSVT7 and pMT2. Vectors derived from bovine papilloma virus include pBV-1MTHA, and vectors derived from Epstein Bar

virus include pHEBO, and p2O5. Other exemplary vectors include pMSG, pAV009/A⁺, pMTO10/A⁺, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of promoters derived from the SV-40 early promoter, SV-40 later promoter, 5 metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, cytomegalovirus promoter, or other promoters shown effective for expression in eukaryotic cells.

While a variety of vectors may be used, it should be noted that 10 retroviral vectors are widely used for modifying eukaryotic cells *in vitro* because of the high efficiency with which the retroviral vectors transfect target cells and integrate into the target cell genome. Additionally, retroviral vectors are capable of infecting cells from a wide variety of tissues.

15

Retroviral vectors are produced by genetically manipulating retroviruses. Retroviruses are RNA viruses because the viral genome is RNA. Upon infection, this genomic RNA is reverse transcribed into a DNA copy which is integrated into the chromosomal DNA of transfected cells 20 with a high degree of stability and efficiency. The integrated DNA copy is referred to as a provirus and is inherited by daughter cells as is any other gene. The wild type retroviral genome and the proviral DNA have three genes: the *gag*, the *pol* and the *env* genes, which are flanked by two long terminal repeat (LTR) sequences. The *gag* gene encodes the 25 internal structural (nucleocapsid) proteins; the *pol* gene encodes the RNA directed DNA polymerase (reverse transcriptase); and the *env* gene encodes viral envelope glycoproteins. The 5' and 3' LTRs serve to promote transcription and polyadenylation of virion RNAs. Adjacent to the 5' LTR are sequences necessary for reverse transcription of the genome 30 (the tRNA primer binding site) and for efficient encapsulation of viral RNA into particles (the Psi site). See Mulligan, R.C., In: Experimental

Manipulation of Gene Expression, M. Inouye (ed), 155-173 (1983); Mann, R. *et al.* (1983), Cell, 33:153-159; Cone, R.D. and Mulligan, R.C., Proceedings of the National Academy of Sciences, U.S.A., 81:6349-6353 (1984).

5

The design of retroviral vectors is well known to one of skill in the art. See Singer, M. and Berg, P., *supra*. In brief, if the sequences necessary for encapsidation (or packaging of retroviral RNA into infectious virions) are missing from the viral genome, the result is a *cis*-acting defect which prevents encapsidation of genomic RNA. However, the resulting mutant is still capable of directing the synthesis of all virion proteins. Retroviral genomes from which these sequences have been deleted, as well as cell lines containing the mutant genome stably integrated into the chromosome are well known in the art and are used to construct retroviral vectors. Preparation of retroviral vectors and their uses are described in many publications including European Patent Application EPA 0 178 220, U.S. Patent 4,405,712, Gilboa, Biotechniques, 4:504-512 (1986), Mann *et al.*, Cell, 33:153-159 (1983), Cone and Mulligan, Proc. Natl. Acad. Sci. USA, 81:6349-6353 (1984), Eglitis, M.A. *et al.*, Biotechniques, 6:608-614 (1988), Miller, A.D. *et al.*, Biotechniques, 7:981-990 (1989), Miller, A.D., (1992), Nature, *supra* (1992), Mulligan, R.C., *supra* (1993), and Gould, B. *et al.*, and International Patent Application No. WO 92/07943 entitled "Retroviral Vectors Useful in Gene Therapy." The teachings of these patents and publications are incorporated herein by reference.

25

Recombinant retroviral vectors useful in the present invention are prepared by inserting a nucleic acid encoding a connexon protein and optionally a drug sensitivity gene into a retrovirus vector and packaging the vector with retroviral capsid proteins by use of a packaging cell line. A packaging cell line is a genetically constructed mammalian tissue culture cell line that produces the necessary viral structural proteins

30

required for packaging, but which itself is incapable of producing infectious virions. On the other hand, retroviral vectors used in conjunction with packaging cell lines lack sequences that encode viral structural proteins but retain the nucleic acid sequences necessary for packaging. To
5 prepare a packaging cell line, an infectious clone of a desired retrovirus, in which the packaging site has been deleted, is constructed. Cells comprising this construct will express all structural proteins but the introduced DNA will be incapable of being packaged. Alternatively, packaging cell lines can be produced by transducing a cell line with one
10 or more expression plasmids encoding the appropriate core and envelope proteins. In these cells, the *gag*, *pol*, and *env* genes can be derived from the same or different retroviruses.

A number of packaging cell lines suitable for the present invention
15 are available in the prior art. Examples of these cell lines include Crip, GPE86, PA317 and PG13. See Miller *et al.*, J. Virol., 65:2220-2224 (1991), which is incorporated herein by reference. Examples of other packaging cell lines are described in Cone, R. and Mulligan, R.C., Proceedings of the National Academy of Sciences, U.S.A., 81:6349-6353
20 (1984), and in Danos, O. and Mulligan, R.C., Proceedings of the National Academy of Sciences, U.S.A., 85:6460-6464 (1988), Eglitis, M.A *et al.*, Biotechniques, 6:608-614 (1988), Miller, A.D. *et al.*, Biotechniques, 7:981-990 (1989), also all incorporated herein by reference. Amphotropic or xenotropic envelope proteins, such as those produced by PA317 and GPX
25 packaging cell lines may also be used to package the retroviral vectors.

The resultant retroviral vector particle is generally incapable of replication in the host cell but is capable of integrating into the host cell genome as a proviral sequence containing the selected nucleic acid. As
30 a result, engineered cells that contain the integrated recombinant vector

are capable of producing the selected connexon protein and the gene product of the drug sensitivity gene.

In addition to the retroviral vectors mentioned above, cells may be
5 transfected with adenoviral or adeno-associated viral vectors. See, e.g.,
Methods in Enzymology, Vol. 185, Academic Press, Inc., San Diego, CA
(D.V. Goeddel, ed.) (1990) or M. Krieger (1990), Gene Transfer and
Expression -- A Laboratory Manual, Stockton Press, New York, NY, and
10 the references cited therein. Adeno associated viruses (AAVs) require
helper viruses such as adenovirus or herpes virus to achieve productive
infection. In the absence of helper virus functions, AAV integrates (site-
specifically) into a host cell's genome, but the integrated AAV genome has
no pathogenic effect. The integration step allows the AAV genome to
15 remain genetically intact until the host is exposed to the appropriate
environmental conditions (e.g., a lytic helper virus), whereupon it re-enters
the lytic life-cycle. Samulski, Current Opinion in Genetic and
Development, 3:74-80 (1993), and the references cited therein provides
an overview of the AAV life cycle. See also West *et al.*, Virology, 160:38-
47 (1987); Carter *et al.*, U.S. Patent No. 4,797,368 (1989); Carter *et al.*,
20 WO 93/24641 (1993); Kotin, Human Gene Therapy, 5:793-801 (1994);
Muzyczka, J. Clin. Invest., 94:1351 (1994), and Samulski, *supra*, for an
overview of AAV vectors.

Plasmids designed for producing recombinant vaccinia, such as
25 pGS62, (Langford, C. L. *et al.*, Mol. Cell. Biol., 6:3191-3199 (1986)) may
also be used. This plasmid consists of a cloning site for insertion of
foreign nucleic acids, the P7.5 promoter of vaccinia to direct synthesis of
the inserted nucleic acid, and the vaccinia TK gene flanking both ends of
the foreign nucleic acid.

2. Cells for expression of connexon protein and cancer therapy

A number of cell types are useful for the practice of this invention and are readily available. These include mammalian non-tumor forming fibroblasts, endothelial cells, smooth muscle cells, parenchymal cells, hematopoietic cells, and lymphoid cells, epithelial cells, bone cells, and keratinocytes. They also include tumor-forming cells which are rendered incapable of forming tumors (for example, by irradiation). These cells may be of rodent, feline, canine, bovine, equine, ovine, nonhuman primate, or human origin. The cells may be primary isolates, immortalized, or genetically modified using techniques known to those of skill in the art.

Specific examples of cell lines useful in the invention are: cell lines which already carry an introduced herpes simplex virus thymidine kinase gene such as PA317, other rodent fibroblast lines which do not carry the HSV-TK gene such as Rat-1, rodent and human tumor cells of different origins with and without the HSV-TK gene such as U87-HSVTK (glioma cells with TK) or SK-MEL-1 (melanoma cells without TK) or cells of special tissue origin such as endothelial cells, HUV-EC-C or lymphocytes such as 5G2.

The culture of cells is well known in the art. Freshney, (Culture of Animal Cells, a Manual of Basic Technique, third edition, Wiley-Liss, New York (1994)), Kuchler *et al.*, Biochemical Methods in Cell Culture and Virology (1977), Kuchler, R.J., Dowden, Hutchinson and Ross, Inc., and the references cited therein provides a general guide to the culture of cells. Cultured cell systems often will be in the form of monolayers of cells, although cell suspensions are also used.

Other cells used in the methods of the present invention can optionally be immortalized by a variety of techniques known in the art, which include transformation with Epstein-Barr virus or with retroviruses, or the transfection of oncogenes. For example, immortalization by Epstein-Barr virus may be employed, as described in U.S. Patent No. 4,464,465, incorporated herein by reference. Epstein-Barr virus mutants which lack OriP and OriLyt origins of replication are particularly useful. Other useful method of immortalization are over-expression of a cellular gene for growth control such as c-myc as described by Bartlett *et al.* (1988), *Proc. Natl. Acad. Sci. USA*, 85: 3255-3259, or using the Rous sarcoma virus long terminal repeat-containing constructs, as described in U.S. Patent No. 5,443,954, both incorporated herein by reference.

The above-mentioned cell lines may be genetically engineered to express genes that increase the survival of cells *in vivo*, such as immortalizing genes of viral origin (e.g., E7 and E1A), proto-oncogenes (e.g., c-myc and H-ras), and oncogenes (e.g., mutated ras), tumor suppressor inactivators (e.g., p16, p21), and apoptosis inactivators (e.g., bcl-2). They may also be genetically modified to express genes that stimulate the delivery cells *in vivo*, e.g., growth factors and growth factor receptors such as alpha or beta fibroblast growth factor, alpha or beta fibroblast growth factor receptor, vascular endothelial growth factor, vascular endothelial growth factor receptor, epidermal growth factor, epidermal growth factor recaptor, platelet-derived growth factor, platelet-derived growth factor receptor, insulin growth factors 1 or 2.

An important element in the transduction experiments is how to decide which cells, vectors and nucleic acids to use. This is generally determined by the identity of the cancer or cancerous tumor to be treated. The cell type and nucleic acids should be chosen to enhance compatibility with the target cancer cell. It is important to first determine which

connexon proteins and cell adhesion molecules are expressed in the target cells, and also their tissue origin. The engineered cells used to treat a particular tumor should preferably contain adhesion molecules and connexon proteins that are compatible, and preferably should be derived
5 from a same or similar tissue.

The degree of compatibility can be tested by an adaptation of the method described in Fick *et al.*, Proc. Nat. Acad. Sci. USA, 92:11071-11075 (1995). Briefly, tumor cell explants are cultured by methods known
10 in the art and labelled with a membrane bound marker such as the fluorescent dye PKH26 (Zynaxis Cell Science, Malvern, PA). The connexon protein- and/or adhesion molecule- and/or pro-drug sensitivity-expressing cell type to be used in tumor therapy is labeled with a cytoplasmic marker capable of passing through gap junctions, such as
15 calcein AM (C-1430, Molecular Probes). The cells are co-cultured under conditions that permit the formation of gap junctions between the two cell types. Gap junctional coupling is expressed as the percentage of labeled (e.g., with PKH26) viable (e.g., using dye exclusion assays) tumor cells in which the cytoplasmic marker (e.g., calcein) is also present. Figure 1
20 depicts the coupling detected between cells in tissue culture. Figure 2 illustrates the bystander killing effect achieved between cells in tissue culture, as described in Fick *et al.* As these figures show, the extent of coupling varies between cell types and may be readily quantified.

25 If cells derived from different tissues, individuals or species are used, it may be important to suppress or control the host organism's immune response in order to prevent unwanted destruction of the engineered cells.

30 The engineered cells used herein may also be cell lines that are capable of inducibly generating replication-defective retroviral particles

capable of infecting adjacent cells. These particles may encode connexon protein molecules, or pro-drug sensitivity genes. Thus the tumor cells of the tumor wherein the cells were injected may be transduced to themselves express connexon protein and/or a pro-drug sensitivity, and
5 to in turn pass these to surrounding tumor cells.

3. Transduction

There are several well-known methods of introducing nucleic acids
10 into animal cells, any of which may be used in the present invention. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing the DNA, treatment of the recipient cells with liposomes containing the DNA, DEAE dextran, receptor-mediated endocytosis, electroporation, micro-injection of the DNA
15 directly into the cells, infection with viral vectors, etc.

4. Detection of expression of connexon protein and selected genes

20 After a given cell is transduced with a nucleic acid construct that encodes a connexon protein and optionally a drug sensitivity gene, it is important to detect which cells and cell lines express connexon protein and to assess the level of expression of connexon protein or a pro-drug activating molecule in engineered cells. This requires the detection of
25 nucleic acids that encode a connexon protein or a pro-drug activating molecule, and also the detection of the protein gene products.

Nucleic acids and proteins are detected and quantified herein by any of a number of means well known to those of skill in the art. These
30 include analytic biochemical methods such as spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance

liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, and various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, and the like. The detection of nucleic acids proceeds by well known methods such as Southern analysis, northern analysis, gel electrophoresis, PCR, radiolabeling, scintillation counting, and affinity chromatography.

10 a. Detection of nucleic acids encoding connexon protein

A variety of methods of specific DNA and RNA measurements and nucleic acid hybridization techniques known to those of skill in the art are useful for detecting and quantifying the presence and expression of connexon protein or pro-drug activating molecules. For example, one method for evaluating the presence of connexon protein DNA in a sample involves a Southern transfer. Southern *et al.*, J. Mol. Biol., 98:503 (1975). Briefly, the digested genomic DNA is run on agarose slab gels in buffer and transferred to membranes. Hybridization is carried out using probes that recognize a connexon protein sequence.

Similarly, a Northern transfer may be used for the detection of connexon protein mRNA in samples of RNA from engineered cells that express the connexon protein gene. In brief, the mRNA is isolated from a given cell sample using an acid guanidinium-phenol-chloroform extraction method. The mRNA is then electrophoresed to separate the mRNA species and the mRNA is transferred from the gel to a nitrocellulose membrane. As with the Southern blots, labeled probes are used to identify the presence or absence of a connexon protein transcript.

The selection of a nucleic acid hybridization format is not critical. A variety of nucleic acid hybridization formats are known to those skilled in the art. For example, common formats include sandwich assays and competition or displacement assays. Hybridization techniques are generally described in "Nucleic Acid Hybridization, A Practical Approach,"
5 Ed. Hames, B.D. and Higgins, S.J., IRL Press, 1985.

The sensitivity of the hybridization assays may be enhanced through use of a nucleic acid amplification system which multiplies the target nucleic acid being detected. *In vitro* amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning are known. Examples of techniques sufficient to direct persons of skill through such *in vitro* amplification methods, including the polymerase chain reaction
10 (PCR) the ligase chain reaction (LCR), Q β -replicase amplification and other RNA polymerase mediated techniques (e.g., NASBA) are found in Berger, Sambrook, and Ausubel, as well as Mullis *et al.*, U.S. Patent No. 4,683,202 (1987); PCR Protocols A Guide to Methods and Applications (Innis *et al.* eds), Academic Press Inc., San Diego, CA (1990) (Innis);
15 Arnheim & Levinson (October 1, 1990), C&EN, 36-47; Kwoh *et al.*, The Journal Of NIH Research, 3:81-94 (1991); Kwoh *et al.*, Proc. Natl. Acad. Sci. USA, 86:1173 (1989); Guatelli *et al.*, Proc. Natl. Acad. Sci. USA, 87:1874 (1990); Lomell *et al.*, J. Clin. Chem., 35:1826 (1989); Landegren *et al.*, Science, 241:1077-1080 (1988); Van Brunt, Biotechnology, 8:291-
20 294 (1990); Wu and Wallace, Gene, 4:560 (1989); Barringer *et al.*, Gene, 89:117 (1990), and Sooknanan and Malek, Biotechnology, 13:563-564 (1995). Improved methods of cloning *in vitro* amplified nucleic acids are described in Wallace *et al.*, U.S. Pat. No. 5,426,039. Other methods recently described in the art are the nucleic acid sequence based
25 amplification (NASBA™, Cangene, Mississauga, Ontario) and Q Beta Replicase systems. These systems can be used to directly identify

mutants where the PCR or LCR primers are designed to be extended or ligated only when a select sequence is present. Alternatively, the select sequences can be generally amplified using, for example, nonspecific PCR primers and the amplified target region later probed for a specific
5 sequence indicative of a mutation.

Oligonucleotides for use as probes, e.g., in *in vitro* amplification methods, for use as gene probes, or as inhibitor components are typically synthesized chemically according to the solid phase phosphoramidite
10 triester method described by Beaucage and Caruthers, Tetrahedron Letts., 22(20):1859-1862 (1981), e.g., using an automated synthesizer, as described in Needham-VanDevanter *et al.*, Nucleic Acids Res., 12:6159-6168 (1984). Purification of oligonucleotides, where necessary, is typically performed by either native acrylamide gel electrophoresis or by
15 anion-exchange HPLC as described in Pearson and Regnier, J. Chrom., 255:137-149 (1983). The sequence of the synthetic oligonucleotides can be verified using the chemical degradation method of Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, Methods in Enzymology, 65:499-560.

20

An alternative means for determining the level of expression of connexon protein is *in situ* hybridization. *In situ* hybridization assays are well known and are generally described in Angerer *et al.*, Methods Enzymol., 152:649-660 (1987). In an *in situ* hybridization assay cells are
25 fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of connexon protein-specific probes that are labelled. The probes are preferably labelled with radioisotopes or fluorescent reporters.

30

b. Detection of connexon protein gene products in engineered cells

5 The expression of connexon protein may be detected or quantified by a variety of methods. Preferred methods involve the use of specific antibodies.

Methods of producing polyclonal and monoclonal antibodies are known to those of skill in the art. See, e.g., Coligan (1991), Current
10 Protocols in Immunology, Wiley/Greene, NY; and Harlow and Lane (1989), Antibodies: A Laboratory Manual, Cold Spring Harbor Press, NY; Stites et al. (eds.) Basic and Clinical Immunology (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Goding (1986), Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press,
15 New York, NY; and Kohler and Milstein, Nature, 256:495-497 (1975). Such techniques include antibody preparation by selection of antibodies from libraries of recombinant antibodies in phage or similar vectors. See, Huse et al., Science, 246:1275-1281 (1989); and Ward et al., Nature, 341:544-546 (1989). Specific monoclonal and polyclonal antibodies and
20 antisera will usually bind with a K_D of at least about .1 mM, more usually at least about 1 μ M, preferably at least about .1 μ M or better, and most typically and preferably, .01 μ M or better.

The presence of a connexin polypeptide (including peptide or
25 enzymatic digestion product) in a sample may be detected and quantified using Western blot analysis. The technique generally comprises separating sample products by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon
30 filter), and incubating the sample with labeling antibodies that specifically bind to the analyte protein. The labeling antibodies specifically bind to

analyte on the solid support. These antibodies are directly labeled, or alternatively are subsequently detected using labeling agents such as antibodies (e.g., labeled sheep anti-mouse antibodies where the antibody to an analyte is a murine antibody) that specifically bind to the labeling
5 antibody.

C. Administration of modified cells to cancer patients

10 1. Selection of patients

The patients to be treated by the methods of the invention are cancer patients. The claimed methods are effective against a range of different cancer types. Preferably the cancer is a tumor-forming cancer.
15 For example, many solid tumors are amenable to treatment using the claimed invention. These tumors include but are not limited to tumors of neuroectodermal derivation (e.g., glioma), carcinomas (e.g., colon cancer, ovarian cancer), and tumors of mesodermal origin (e.g., sarcomas).

20 2. Pre-testing for efficacy against a particular cancer

In order to assess how well the methods of the invention may be expected to work, the clinician can pre-test the efficacy of the treatment of a particular tumor type either *in vitro* or *in vivo*.

25

For *in vitro* tests, cells derived from the tumor are grown in tissue culture. The method described in Fick *et al.* is used to assess the efficacy of using a particular engineered cell line to transfer therapeutic molecules to the tumor-derived cells. The growth inhibiting effect may be assessed

30

using a number of commonly used assays, such as the methylcellulose assay (Lunardi-Iskandar *et al.*, Clin. Exp. Immunol., 60:285-293 (1985)).

5 3. Methods of administration and dosages

Administration of cells to a cancer patient can be achieved in various ways known to skilled practitioners. The cells can be injected intratumorally: the tumor, the placement of the needle and release of the
10 contents of the syringe are visualized either by direct observation (for easily accessible tumors such as surface tumors or tumors easily exposed by surgical techniques), by endoscopic visualization, or by electromagnetic imaging techniques such as ultrasound, magnetic resonance imaging (MRI), CT scans. The cells can also be administered via injection into the
15 bloodstream using a cannula or catheter; the vein or artery is selected to maximize delivery of cells to the tumor or affected tissue. The cells can be injected into cerebro-spinal fluid (*i.e.*, into intracisternal, intraventricular, intrathecal or subarachnoid compartments). In cystic or vesicular tumors or tissues, the cells may be delivered intracystically or intravesicularly.

20 It is contemplated that the cells will be administered under the guidance of a physician. The concentration and number of cells to be administered at a given time and to a given patient will vary from 10^5 to 10^{10} cells per patient. Generally, the number of cells to be administered
25 is the amount necessary to reduce cancer cell growth and/or to destroy cancer cells and/or preferably to eradicate the cancer. The exact number is a function of the size and compactness (or diffuseness) of the particular transformed cell mass to be treated, and the distance or accessibility of the tissue to be treated from the point of administration of the cells. More
30 than one administration may be necessary. As with any medical treatment, the supervising physician will monitor the progress of the

treatment, and will determine whether a given administration is successful and sufficient, or whether subsequent administrations are needed.

The injected cells and cells junctionally coupled to them may be destroyed by administration of a pro-drug to the patient that will target for destruction the injected cells and cells that are junctionally coupled to them. For example, the enzyme cytosine deaminase converts 5-fluorocytosine ("5FC") into the lethal metabolite 5-fluorouracil ("5FU"). Engineered administered cells that are induced to produce cytosine deaminase by virtue of having the cytosine deaminase gene introduced into and expressed in the host cell, when exposed to 5FC, will die as a result of the formation of 5FU. Another gene that confers drug sensitivity upon a host cell is the thymidine kinase gene, which confers sensitivity to ganciclovir. Administration of the pro-drug may be local or systemic and may be achieved by any of the methods for administration of the cells.

4. Monitoring treatment

Tumor regression and other parameters of successful treatment are assessed by methods known to persons of skill in the art. This includes any imaging techniques that are capable of visualizing cancerous tissues (e.g., MRI), biopsies, methods for assessing metabolites produced by the cancer tissue or affected tissue in question, the subjective well-being of the patient, etc.

25

EXAMPLES

Example 1:

This example shows that *in vivo* Ganciclovir (GCV) tumor toxicity which results from exposure of tumor cells to fibroblast cell lines

30

that express the thymidine kinase (*tk*) gene increases as a function of ability to carry out gap junction-mediated intercellular communication.

The HSV-*tk* gene encodes an activity capable of converting the non-cytotoxic molecule GCV to a cytotoxic one. Cells that are exposed to harmful levels of the cytotoxic molecule die.

The HSV-*tk* gene was stably cloned into a PA317 fibroblasts as described in Mol. Cell. Biol. 6:2895-2902 (1986) and New Eng. J. Med. 232:570-578 (1990). Athymic (immune-incompetent) BALB/C mice were injected subcutaneously with mixtures of: 1) 1×10^7 tumor cells known to have either high (9L glial tumor cells) or low (C6 glial tumor cells) levels of gap junction mediated intercellular transport, and 2) 1×10^7 immortalized mouse fibroblasts (PA317 cells) engineered to express HSV-TK. The mixtures of inoculated cells were allowed to grow into tumors over a period of 7-14 days (the time for detectable tumor formation varied depending on the identity and number of injected cells). The tumor-bearing animals were then treated for 7 days with GCV (25 mg/kg, BID) or with phosphate buffered saline (PBS). Tumor size was periodically monitored.

14 days following the initiation of GCV treatment the tumors were removed. Figure 3 summarizes the average weight of tumors following their removal. As can be appreciated in Figure 3, the tumors from animals exposed to 9L cells and GCV were significantly smaller than the tumors from animals exposed to 6L cells and GCV. Thus, tumor toxicity was greater in tumors with higher levels of gap junction mediated intercellular transport. In other words, tumors consisting of cells known to be able to avidly exchange molecules with the fibroblasts expressing HSV-TK (9L cells) and thereby easily pass cytotoxic molecules through

gap junctions were more effectively killed by bystander effect *in vivo* than cells which did not as effectively form gap junctions.

Example 2:

5

Example 2 demonstrates that injecting HSV tk -expressing fibroblasts into *pre-existing* tumors is effective to decrease tumor mass, and that the toxicity is greater in tumors with higher gap junction mediated intercellular transport.

10

5 athymic (immuno-incompetent) mice were injected subcutaneously with 1×10^7 tumor cells known to have either high (9L glial tumor cells) or low (C6 glial tumor cells) levels of gap junction mediated intercellular transport. 1×10^7 HSV- tk^+ fibroblasts (PA317 cells) were injected into the center of tumors that were formed. GCV therapy (25 mg/kg, BID) was commenced 24 hours later and continued for 7 days. 14 days following the initiation of GCV treatment the tumors were removed and weighed.

20

Figure 4 illustrates that the effect of GCV treatment was greater in 9L cells. These findings indicate the importance of gap junction mediated transport for the bystander killing of tumor cells. Established tumors of cells known to be able to avidly exchange molecules with the fibroblasts expressing HSV-TK and thereby easily pass cytotoxic molecules through gap junctions (9L cells) were more effectively killed by bystander effect than are cells which did not as effectively form gap junctions (C6 cells) under conditions which mimic closely the conditions under which this therapy would be used clinically.

30

Example 3:

This example illustrates that the expression of connexon proteins such as connexin43 modulates GCV tumor toxicity.

5

To evaluate the role of connexin and gap junctions in the *in vivo* GCV tumor cytotoxicity, HSV-*tk* was expressed in fibroblast cells which were derived from a mouse in which both copies of the connexin43 gene had been deleted from its genome (genetic constitution). We then
10 examined the ability of these connexin43⁻ fibroblasts and comparable fibroblasts derived from normal mice to mediate intercellular gap junction mediated transport.

Fibroblasts from connexin43⁻ mice or wild type mice were
15 labeled with a cytoplasmic fluorescent dye, Calcein AM. 9L and HT1335 tumor cells were labeled with a membrane-bound fluorescent dye, PKH26. 10⁶ Calcein AM-labeled fibroblasts and 10⁶ PKH26-labeled tumor cells were seeded in 6 well plate's and incubated for 3.5 hrs. Cells were washed with Cu⁺⁺/Mg⁺⁺-free phosphate buffeted saline (PBS),
20 trypsinized, centrifuged, and resuspended in PBS containing 0.3% FBS, 0.03 μ g/ml propidium iodide and 0.3 μ g/ml Hoechst 33342. After 30 min., cells were analyzed by flow cytometry using a dual laser system. Calcein and PKH26 emissions were excited with a 488 nm argon laser and collected through 525/25 and 575/25 nm band pass filters, respectively.
25 Hoechst 33342 emissions were excited with a 354/363 nm argon laser and collected through a 470/25 nm band pass filter. Data from 20,000 cells were acquired from each sample. Dead cells were excluded by gating based on cellular forward light scatter and propidium iodide fluorescence. Fluorescence signals were measured on a four decades
30 logarithmic scale and cell phases were analyzed on a 1024 channel linear scale. Coupling was detected by the identification of viable

PKH26-labeled tumor cells in which calcein fluorescence was also detected.

Figure 5 is a composite of the results obtained from experiments in which different cells were labeled, incubated and evaluated for coupling. The x,y axis demarcations are in arbitrary FACS units indicating the intensity of fluorescence of the indicated dyes and the z axis marks the relative number of cells characterized by a specific fluorescence pattern. The pattern cell types were examined in the experiments shown in Figure 5: Panel A) connexin43⁻ fibroblasts and 9L tumor cells, Panel B) wildtype fibroblasts and 9L tumor cells. Panel C) connexin43⁻ fibroblasts and HT1335 tumor cells, Panel D) wildtype fibroblasts and HT1335 tumor cells.

These results indicate the connexin43⁻ fibroblasts do not mediate gap junction intercellular transport with tumor cell lines (Panel A, C), from rat (9L) or from human (HT1335), whereas wildtype fibroblasts do (Panels B, D). Since the only difference between the wildtype and connexin43⁻ fibroblasts is the absence of a connexin43 gene, this indicates that this genes is required for gap junction mediated transport in these cells. These findings demonstrate that expression of connexin43 is required for bystander-mediated killing and an effective prodrug activation gene therapy. Connexin43⁻ fibroblasts would not be effective treatment vehicles for gene therapy strategies that depended upon bystander cell killing to be effective.

Example 4:

Example 4 illustrates that the *in vivo* tumor toxicity observed in Examples 1 and 2 involves the expression of connexon proteins such

as connexin43. Here, the efficacy of GCV to inhibit tumor growth of 9L tumor cell mouse xenografts grown in the presence of HSV-TK fibroblasts which express connexin43 was compared to the efficacy of HSV-TK⁺, connexin43⁻ fibroblasts.

5

5 athymic (immuno-incompetent) mice were injected subcutaneously with *mixtures* of 1×10^7 9L tumor cells and either immortalized connexin43- mouse fibroblasts engineered to express HSV-*tk* (5 mice) or immortalized mouse fibroblasts from normal mice which
10 express connexin 43 and had also been engineered to express HSV-*tk* (5 mice). The inoculated cells were allowed to grow into tumors. The tumor-bearing animals were treated with GCV (25 mg/kg) for 7 days. Tumor size was monitored and 14 days following the initiation of GCV treatment the tumors were removed. In a parallel experiment, animals
15 injected with a mixture of 1×10^7 9L tumor cells and with immortalized connexin43⁻ mouse fibroblasts engineered to express HSV-*tk* were mock-treated with sham injections of phosphate buffered saline (PBS) lacking Ganciclovir.

20

GCV administration had a highly therapeutic effect against tumors which contained fibroblasts with normal gap junction (normal connexin 43 genes), but was not effective in treating tumors consisting of 9L cells and HSV-*tk*4+ fibroblasts in which the connexin genes had been deleted (Fig. 6). Of the 5 animals with tumors consisting of 9L cells and
25 HSV-*tk*⁺ fibroblasts expressing connexin43, only 3 animals still had detectable tumors when examined 7 days after the completion of GCV therapy. These tumors had an average weight of 0.63 g. A matched control group of 5 animals which received sham injections of phosphate buffered saline (PBS) instead of GCV all had tumors 7 days after the
30 completion of this "sham treatment". The tumors had an average weight of 4.35 g.

Two other groups of 5 animals inoculated with mixtures of 9L cells and HSV-*tk*⁺ fibroblasts derived from cells lacking any connexin43 genes were identically treated. Those which did not receive GCV all had tumors, and the average weight of these tumors was 5.68 g. All 5 animals in the group inoculated with 9L cells and connexin43⁻ fibroblasts also had tumors, even after 7 days of GCV treatment; the tumors had an average weight of 5.43 g.

Thus, tumors consisting of cells known to be able to avidly exchange molecules with the fibroblasts expressing HSV-*tk* and thereby easily pass cytotoxic molecules through gap junctions were more effectively killed by bystander effect *in vivo* than cells which ineffectively form gap junctions; namely, HSV-*tk*⁺/connexin43⁻ fibroblasts. These findings indicate that connexin gene expression is required for gap junction mediated intercellular transport which mediates the bystander killing of tumor cells *in vivo*, and contributes to the optimization of gene therapy strategies such as viral prodrug activation which require bystander cell killing to be efficacious.

20 Example 5

In one embodiment of the invention, patients diagnosed as having metastatic ovarian cancer of the peritoneal cavity are treated as follows:

25 1. Engineered cells

Commercially obtained NIH3T3 cells are genetically engineered to express thymidine kinase and connexin 43 as follows: The vector pcDNA3-HSVTK, which contains a cDNA clone encoding the Herpes simplex virus thymidine kinase (HSV-TK) gene is constructed by standard technologies in pcDNA3 obtained from Invitrogen (San Diego, California).

pBluescript-HSV-TK DNA is digested with BamH1 restriction enzyme and the fragment containing the HSV-TK coding region is isolated. The vector pcDNA (obtained from Invitrogen) containing a neomycin resistance gene is digested with restriction enzymes BamH1 and the HSV-TK coding
5 fragment is ligated into the BamH1 site of the expression vector. The resulting pcDNA3-HSVTK vector is cloned by the standard technologies. See Molecular Cloning - A Laboratory Manual (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, N.Y., (Sambrook); and F.M. Ausubel *et al.*, Current Protocols in Molecular Biology, eds.,
10 Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (1994 Supplement) (Ausubel). The plasmid vector pBluescript containing the recombinant cDNA encoding chicken connexin43 (obtained from Dr. Eric Beyer Washington University) is digested with restriction enzyme EcoRI and the fragment containing the
15 connexin43 coding region is isolated. The vector pMEP4 which contains the hygromycin resistance gene for selection is digested in the restriction enzyme EcoRI. The connexin43 fragment is ligated into the EcoRI site, and the resulting pMEP4-Cx43 vector is cloned. This pMEP4-Cx43 encodes both connexin43 and a hygromycin resistance gene.

20

NIH3T3 cells are transfected with the pcDNA3-HSVtk vector
using the calcium phosphate technique described in Molecular Cloning - A Laboratory Manual (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, N.Y. (Sambrook); and Ausubel, F.M. *et al.*,
25 Current Protocols in Molecular Biology, eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (1994 Supplement) (Ausubel). Transfected cell clones are selected in neomycin. Individual clones are tested for the expression of the tk cDNA by Northern and Southern blots and by immunoassays using
30 anti-thymidine kinase antibodies. Thymidine kinase expression is also determined by testing sensitivity to ganciclovir, as described by Fick *et al.*

Selected NIH3T3-TK clones generated above are then transfected with the pMEP4-Cx43 vector as described above. NIH3T3-TK-CX clones are obtained by incubating the cells in neomycin and hygromycin. Individual NIH3T3-TK-CX clones are tested for the expression of the TK and connexin cDNA by Northern and Southern blots and by immunoassays using anti-thymidine kinase and anti-connexin 43 antibodies. Thymidine kinase expression is also determined by testing sensitivity to ganciclovir, as described by Fick *et al.* Likewise, PA317 cells, which are NIH3T3 cells expressing HSV-tk, can be transfected with the above described pMEP-Cx43, selected in hygromycin, evaluated for expression of tk and connexin, and tested for ganciclovir sensitivity as described above.

Clones having a heightened ability to form functional gap junctions can be identified by the method described in Fick *et al.* using appropriate cells as the assay partner, such as C6 or U87 cells. The ability of these clones to mediate bystander killing are determined by the method described in Fick *et al.* Cells with the highest activity in the bystander killing assay are used for *in vivo* cancer treatments.

Freshly made or cryopreserved NIH-TK-Cx43 or PA317-Cx43 clones exhibiting a high bystander killing ability are injected directly into the peritoneal cavity of a patient either by peritoneal injection or under direct visualization with peritonoscopy. The diagnosis of a tumor is made by any of the evaluation of peritoneal fluid, peritoneal washes, or biopsy of peritoneal tumor implants. The presumptive diagnosis is confirmed at the time of surgery by a pathologist who evaluates a specimen removed by the surgeon or oncologist who collected the pathological specimen. The injected, engineered cells are allowed to establish contact with the tumor cells for an appropriate time period (for example, 4-72 hours.) The patient is then treated with the pro-drug ganciclovir intravenously.

Inhibition of tumor growth can be monitored by serial evaluations of the peritoneal cavity by MRI scanning, direct visualization by peritonoscopy, or examination of peritoneal fluid or wash fluid for malignant cellular elements.

5

Example 6.

In another embodiment of the invention, patients diagnosed as having an intracranial meningioma are treated as follows:

10

1. Engineered cells

Commercially obtained PA317 cells which are genetically modified 3T3 cells that express thymidine kinase are engineered to express
15 connexin 43 as follows: The plasmid vector pBluescript containing the recombinant cDNA encoding chicken connexin43 (obtained from Dr. Eric Beyer, Washington University) is digested with restriction enzyme EcoRI, and the fragment containing the connexin43 coding region is isolated. The vector pMEP4 which contains the hygromycin resistance gene for
20 selection is digested with the restriction enzyme EcoRI. The connexin43 fragment is ligated into the EcoRI site, and the resulting pMEP4-Cx43 vector is cloned. This pMEP4-Cx43³ encodes both connexin43 and a hygromycin resistance gene.

25

PA317 cells are transfected with the pMEP-4-Cx43 vector using the calcium phosphate technique described in Molecular Cloning - A Laboratory Manual (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, N.Y. (Sambrook); and Ausubel, F.M. *et al.*, Current Protocols in Molecular Biology, eds., Current Protocols, a joint
30 venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (1994 Supplement) (Ausubel). Transfected cell clones are

selected in hygromycin. Thymidine kinase expression is also determined by testing sensitivity to ganciclovir, as described by Fick *et al.*

Individual PA317-CX43 clones are tested for the expression of the
5 connexin43 cDNA by Northern and Southern blots and by immunoassays using anti-connexin 43 antibodies. Thymidine kinase expression is also determined by testing sensitivity to ganciclovir, as described by Fick *et al.*

Clones have a heightened ability to form functional gap junctions
10 are identified by the method of Fick *et al.*, using as the assay partner a human glioma tumor cell line with low coupling (serving as a sensitive monitor) such as SF295. The ability of these clones to mediate bystander killing are determined by the method described in Fick *et al.* Cells with the highest activity in the bystander killing assay are used for *in vivo*
15 cancer treatments.

2. Treatment of patients

Freshly made or cryopreserved NIH3T3-TK-CX clones exhibiting a high bystander killing ability are injected directly into the brain tumors of a patient under direct visualization at the time of surgery. The diagnosis of a tumor is made by any neuroimaging modality which allows the localization and characterization of a tumor. The presumptive diagnosis is confirmed at the time of surgery by a pathologist who evaluates a surgical specimen removed by the surgeon. The injected engineered cells are allowed to establish contact with the tumor cells for an appropriate time (for example, 4-72 hours). The patient is then treated with the pro-drug ganciclovir intravenously. Inhibition of tumor growth can be monitored by serial MRI scans.

CLAIMS

We claim:

- 5 1. A method of inhibiting the growth of tumor cells and solid tumors, which method comprises:
- a) providing engineered non-tumorigenic cells that express a first heterologous nucleic acid that encodes a connexon protein and a second heterologous nucleic acid that encodes a pro-drug activating molecule that
- 10 converts a non-toxic substrate to a toxic product, and
- b) contacting tumor cells in a solid tumor with cells of step a that form functional gap junctions with said tumor cells, then
- c) exposing the engineered and tumor cells to a therapeutic amount of a non-toxic substance that is converted to a toxic product in cells that
- 15 express the pro-drug activating molecule, wherein the toxic product then passes through gap junctions to adjacent coupled tumor cells, thereby inhibiting the cell growth of the tumor cells that contain the toxic product.
2. A method according to claim 1, wherein the non-tumorigenic
- 20 engineered cells are selected from the group that consists of engineered non-tumorigenic fibroblasts, epithelial cells, endothelial cells, bone cells, keratinocytes, and irradiated, engineered non-tumorigenic cells derived from tumors.
3. A method according to claim 2, wherein the non-tumorigenic
- 25 engineered cells are PA317 fibroblasts.
4. A method according to claim 1, wherein the tumor cells are selected from the group of tumor cells that consist of embryonal tumors,
- 30 sarcomas, carcinomas, and tumors of neuroectodermal origin.

5. A method according to claim 1, wherein the tumor cells are selected from the group of human tumor cells that consist of glioma cells, colon carcinoma cells, osteosarcoma cells, and neuroblastoma cells.

5 6. A method according to claim 1, wherein the pro-drug activating molecule is selected from the group that consists of thymidine kinase, cytosine deaminase, and β -glucosidase.

7. A method according to claim 1, wherein the connexon protein is
10 selected from the group that consists of connexin 26, connexin 32, connexin 43 and connexin 45.

8. A method according to claim 1, wherein the connexon protein is ductin.

15

9. A method according to claim 1, wherein the engineered cell and the target cell are from the same individual.

10. A method according to claim 1, wherein the engineered cells
20 further express a heterologous nucleic acid that encodes a molecule that enables, mediates or enhances gap junctional communication.

11. A method for the enhanced intracellular delivery of a therapeutically active molecule to a target tumor cell, which method
25 comprises:

a) providing engineered non-tumorigenic cells that contain a therapeutically active molecule that passes through gap junctional channels, wherein the engineered cells express a heterologous nucleic acid that encodes a connexon protein that is a predominant connexon
30 protein expressed in tumor cells described in step b, and

b) contacting target tumor cells in a solid tumor with cells of step a that form functional gap junctions with said target tumor cells, whereby the molecule passes through a gap junction to a target tumor cell.

- 5 12. A method according to claim 11, wherein the non-tumorigenic engineered cells are selected from the group that consists of engineered non-tumorigenic fibroblasts, epithelial cells, endothelial cells, bone cells, keratinocytes, and irradiated, engineered non-tumorigenic cells derived from tumors.
- 10 13. A method according to claim 12, wherein the non-tumorigenic engineered cells are PA317 fibroblasts.
- 15 14. A method according to claim 11, wherein the therapeutically active molecule is selected from the group that consists of thymidine kinase, cytosine deaminase, and β -glucosidase.
- 20 15. A method according to claim 11, wherein the connexin is selected from the group that consists of connexin 26, connexin 32, connexin 43 and connexin 45.
- 25 16. A method according to claim 11, wherein the engineered cells and the target tumor cells are derived from the same individual.
- 30 17. A composition for the enhanced delivery of a toxic metabolite to a target tumor cell, which composition comprises an engineered non-tumorigenic cell that expresses a first heterologous nucleic acid that encodes a connexin and a second heterologous nucleic acid that encodes a pro-drug activating molecule that converts a non-toxic substrate to a toxic metabolite.

18. A composition of claim 17, wherein the engineered non-tumorigenic cell is selected from the group that consists of engineered fibroblasts, epithelial cells, endothelial cells, bone cells, keratinocytes, and irradiated, engineered non-tumorigenic cells derived from tumors.

5

19. A composition for the enhanced delivery of a therapeutically active molecule to a target tumor cell, which composition comprises an engineered non-tumorigenic cell that contains a therapeutically active molecule and expresses a heterologous nucleic acid that encodes a

10 connexon protein.

20. A composition of claim 19, wherein the engineered non-tumorigenic cell is selected from the group that consists of engineered fibroblasts, epithelial cells, endothelial cells, bone cells, keratinocytes, and

15 irradiated, engineered non-tumorigenic cells derived from tumors.

1/5





FIG. 1

2/5

FIG. 2



3/5

FIG. 3




FIG. 4




FIG. 5B





FIG. 5D

FIG. 5A






FIG. 5C

FIG. 6



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/01434

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/04; A61K, 31/70; A01N 63/00
US CL : 536/23.1; 514/44; 424/93.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1; 514/44; 424/93.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, MEDLINE, EMBASE, CANCERLIT, HCAPLUS, APS, REGISTRY
search terms: gap junction, connexon, prodrug, ductin, engineered cell

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FICK et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA. November 1995, Vol. 92, pages 11071-11075, especially pages 11071-11073.	1-7 and 10-20
Y	COLOMBO et al. The "Bystander Effect": Association of U-87 Cell Death with Ganciclovir-Mediated Apoptosis of Nearby Cells and Lack of Effect in Athymic Mice. Human Gene Therapy. June 1995, Vol. 6, pages 736-772, especially pages 763-765.	1-7 and 10-20

☒

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A		document defining the general state of the art which is not considered to be of particular relevance
* E	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* L	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* O		document referring to an oral disclosure, use, exhibition or other means
* P	* &	document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search

03 APRIL 1997

Date of mailing of the international search report

19.05.1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SUSAN UNGAR

Telephone No. (703) 308-0496

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/01434

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	MESNIL et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA. March 1996, Vol. 93, pages 1831-1835, especially pages 1831-1833.	1,2,4-7,10-12, and 14-20
Y,P	HAMEL et al. Herpes Simplex Virus Thymidine Kinase/Ganciclovir-mediated Apoptotic Death of Bystander Cells. Cancer Research. 15 June 1996, Vol. 56, pages 2697-2702, especially pages 2697-2698.	1-7 and 10-20
Y, f	US 5,591,625 A (GERSON ET AL) 07 January 1997, see entire document, especially columns 1-3.	9

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/01434

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim(s) 1-10 and 17-20, drawn to a method of inhibiting the growth of tumor cells and solid tumors by delivering a prodrug activating molecule and a composition that encodes a prodrug activating molecule.

Group II, claim(s) 11-16, drawn to a method for the enhanced delivery of a therapeutically active molecule to a target tumor cell.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I contains the special technical feature of a method and a composition for inhibiting the growth of tumor cells and solid tumors that is not found in Group II.

Group II contains the special technical feature of a method for the enhanced delivery of a therapeutically active molecule to a target tumor cell that is not found in Group I.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)